372 related articles for article (PubMed ID: 27782193)
21. Lipocalin 2 negatively regulates cell proliferation and epithelial to mesenchymal transition through changing metabolic gene expression in colorectal cancer.
Kim SL; Lee ST; Min IS; Park YR; Lee JH; Kim DG; Kim SW
Cancer Sci; 2017 Nov; 108(11):2176-2186. PubMed ID: 28859238
[TBL] [Abstract][Full Text] [Related]
22. N-myc downstream-regulated gene 2 inhibits human cholangiocarcinoma progression and is regulated by leukemia inhibitory factor/MicroRNA-181c negative feedback pathway.
Wang J; Xie C; Pan S; Liang Y; Han J; Lan Y; Sun J; Li K; Sun B; Yang G; Shi H; Li Y; Song R; Liu X; Zhu M; Yin D; Wang H; Song X; Lu Z; Jiang H; Zheng T; Liu L
Hepatology; 2016 Nov; 64(5):1606-1622. PubMed ID: 27533020
[TBL] [Abstract][Full Text] [Related]
23. The H4 histamine receptor agonist, clobenpropit, suppresses human cholangiocarcinoma progression by disruption of epithelial mesenchymal transition and tumor metastasis.
Meng F; Han Y; Staloch D; Francis T; Stokes A; Francis H
Hepatology; 2011 Nov; 54(5):1718-28. PubMed ID: 21793031
[TBL] [Abstract][Full Text] [Related]
24. Serum Apurinic/Apyrimidinic Endodeoxyribonuclease 1 (APEX1) Level as a Potential Biomarker of Cholangiocarcinoma.
Tummanatsakun D; Proungvitaya T; Roytrakul S; Limpaiboon T; Wongkham S; Wongkham C; Silsirivanit A; Somintara O; Sangkhamanon S; Proungvitaya S
Biomolecules; 2019 Aug; 9(9):. PubMed ID: 31454981
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of KLHL21 prevents cholangiocarcinoma progression through regulating cell proliferation and motility, arresting cell cycle and reducing Erk activation.
Chen J; Song W; Du Y; Li Z; Xuan Z; Zhao L; Chen J; Zhao Y; Tuo B; Zheng S; Song P
Biochem Biophys Res Commun; 2018 May; 499(3):433-440. PubMed ID: 29574153
[TBL] [Abstract][Full Text] [Related]
26. Tumour stroma-derived lipocalin-2 promotes breast cancer metastasis.
Ören B; Urosevic J; Mertens C; Mora J; Guiu M; Gomis RR; Weigert A; Schmid T; Grein S; Brüne B; Jung M
J Pathol; 2016 Jul; 239(3):274-85. PubMed ID: 27038000
[TBL] [Abstract][Full Text] [Related]
27. Aberrant expression of GATA binding protein 6 correlates with poor prognosis and promotes metastasis in cholangiocarcinoma.
Tian F; Li D; Chen J; Liu W; Cai L; Li J; Jiang P; Liu Z; Zhao X; Guo F; Li X; Wang S
Eur J Cancer; 2013 May; 49(7):1771-80. PubMed ID: 23313142
[TBL] [Abstract][Full Text] [Related]
28. Hepatocyte nuclear factor 6 inhibits the growth and metastasis of cholangiocarcinoma cells by regulating miR-122.
Zhu H; Mi Y; Jiang X; Zhou X; Li R; Wei Z; Jiang H; Lu J; Sun X
J Cancer Res Clin Oncol; 2016 May; 142(5):969-80. PubMed ID: 26825606
[TBL] [Abstract][Full Text] [Related]
29. High-mobility group box 1 expression and lymph node metastasis in intrahepatic cholangiocarcinoma.
Xu YF; Ge FJ; Han B; Yang XQ; Su H; Zhao AC; Zhao MH; Yang YB; Yang J
World J Gastroenterol; 2015 Mar; 21(11):3256-65. PubMed ID: 25805932
[TBL] [Abstract][Full Text] [Related]
30. Sprouty4 correlates with favorable prognosis in perihilar cholangiocarcinoma by blocking the FGFR-ERK signaling pathway and arresting the cell cycle.
Qiu B; Chen T; Sun R; Liu Z; Zhang X; Li Z; Xu Y; Zhang Z
EBioMedicine; 2019 Dec; 50():166-177. PubMed ID: 31761616
[TBL] [Abstract][Full Text] [Related]
31. MicroRNA-21 regulates biological behavior by inducing EMT in human cholangiocarcinoma.
Liu Z; Jin ZY; Liu CH; Xie F; Lin XS; Huang Q
Int J Clin Exp Pathol; 2015; 8(5):4684-94. PubMed ID: 26191158
[TBL] [Abstract][Full Text] [Related]
32. Blockade of CXCL12/CXCR4 signaling inhibits intrahepatic cholangiocarcinoma progression and metastasis via inactivation of canonical Wnt pathway.
Zhao S; Wang J; Qin C
J Exp Clin Cancer Res; 2014 Dec; 33(1):103. PubMed ID: 25471741
[TBL] [Abstract][Full Text] [Related]
33. Over-expression of lipocalin 2 promotes cell migration and invasion through activating ERK signaling to increase SLUG expression in prostate cancer.
Ding G; Fang J; Tong S; Qu L; Jiang H; Ding Q; Liu J
Prostate; 2015 Jun; 75(9):957-68. PubMed ID: 25728945
[TBL] [Abstract][Full Text] [Related]
34. EGF/EGFR axis contributes to the progression of cholangiocarcinoma through the induction of an epithelial-mesenchymal transition.
Clapéron A; Mergey M; Nguyen Ho-Bouldoires TH; Vignjevic D; Wendum D; Chrétien Y; Merabtene F; Frazao A; Paradis V; Housset C; Guedj N; Fouassier L
J Hepatol; 2014 Aug; 61(2):325-32. PubMed ID: 24704591
[TBL] [Abstract][Full Text] [Related]
35. aPKC-ι/P-Sp1/Snail signaling induces epithelial-mesenchymal transition and immunosuppression in cholangiocarcinoma.
Qian Y; Yao W; Yang T; Yang Y; Liu Y; Shen Q; Zhang J; Qi W; Wang J
Hepatology; 2017 Oct; 66(4):1165-1182. PubMed ID: 28574228
[TBL] [Abstract][Full Text] [Related]
36. Silencing of LAMC2 Reverses Epithelial-Mesenchymal Transition and Inhibits Angiogenesis in Cholangiocarcinoma via Inactivation of the Epidermal Growth Factor Receptor Signaling Pathway.
Pei YF; Liu J; Cheng J; Wu WD; Liu XQ
Am J Pathol; 2019 Aug; 189(8):1637-1653. PubMed ID: 31345467
[TBL] [Abstract][Full Text] [Related]
37. Serum and bile biomarkers for cholangiocarcinoma.
Alvaro D
Curr Opin Gastroenterol; 2009 May; 25(3):279-84. PubMed ID: 19396965
[TBL] [Abstract][Full Text] [Related]
38. Suppression of trophoblast cell surface antigen 2 enhances proliferation and migration in liver fluke-associated cholangiocarcinoma.
Sawanyawisuth K; Tantapotinan N; Wongkham C; Riggins GJ; Kraiklang R; Wongkham S; Puapairoj A
Ann Hepatol; 2016; 15(1):71-81. PubMed ID: 26626643
[TBL] [Abstract][Full Text] [Related]
39. Nimotuzumab Inhibits Cholangiocarcinoma Cell Metastasis
Padthaisong S; Thanee M; Techasen A; Namwat N; Yongvanit P; Liwatthakun A; Hankla K; Sangkhamanon S; Loilome W
Anticancer Res; 2017 Jul; 37(7):3591-3597. PubMed ID: 28668850
[TBL] [Abstract][Full Text] [Related]
40. Arctigenin inhibits cholangiocarcinoma progression by regulating cell migration and cell viability via the N-cadherin and apoptosis pathway.
Janthamala S; Jusakul A; Kongpetch S; Kimawaha P; Klanrit P; Loilome W; Namwat N; Techasen A
Naunyn Schmiedebergs Arch Pharmacol; 2021 Oct; 394(10):2049-2059. PubMed ID: 34283274
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
